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AbstrAct
Introduction Although physical activity may reduce 
disease burden, fatigue and disability, and improve 
quality of life among people with multiple sclerosis (MS), 
many people with MS are physically inactive and spend 
significant time in sedentary behaviour. Behaviour change 
interventions may assist people with MS to increase 
physical activity and reduce sedentary behaviour. However, 
few studies have investigated their effectiveness using 
objective measures of physical activity, particularly in the 
long term. Further, interventions that have proven effective 
in the short term may not be feasible in clinical practice 
because of the large amount of support provided. The 
iStep-MS trial aims to determine the safety, feasibility 
and acceptability of a behaviour change intervention to 
increase physical activity and reduce sedentary behaviour 
among people with MS.
Methods and analysis Sixty people with MS will be 
randomised (1:1 ratio) to receive a 12-week intervention 
or usual care only. The intervention consists of four 
physical activity consultations with a physiotherapist 
supported by a handbook and pedometer. Outcomes 
assessed at baseline, 12 weeks and 9 months are 
physical activity (ActiGraph wGT3X-BT accelerometer), 
sedentary behaviour (activPAL3µ), self-reported activity 
and sitting time, walking capability, fatigue, self-efficacy, 
participation, quality of life and health service use. 
The safety of the intervention will be determined by 
assessing change in pain and fatigue and the incidence 
of adverse events during the follow-up period. A parallel 
process evaluation will assess the feasibility and 
acceptability of the intervention through assessment of 
fidelity to the programme and semistructured interviews 
exploring participants’ and therapists’ experiences of the 
intervention. The feasibility of conducting an economic 
evaluation will be determined by collecting data on quality 
of life and resource use.
Ethics and dissemination Research ethics committee 
approval has been granted from Brunel University London. 
Results of the trial will be submitted for publication 
in journals and distributed to people with MS and 
physiotherapists.
trial registration number ISRCTN15343862 (doi 
10.1186/ISRCTN15343862). Protocol version: 1.0; Pre-
results.
IntroductIon
Multiple sclerosis (MS) is typically a progres-
sive and unpredictable condition of the 
central nervous system that is a major cause of 
neurological disability among young adults.1 
As a consequence of MS, people experience 
disorders of mobility, balance, sensation, 
cognition and vision.2 There is also consis-
tent evidence that people with MS participate 
in low levels of physical activity and spend 
increased time in sedentary behaviour.3–6 
Increasing physical activity and reducing 
sedentary behaviour may have specific bene-
fits for people with MS. Those who participate 
in high levels of physical activity and spend 
little time in sedentary behaviour have milder 
disability, better mental health, better social 
functioning, less fatigue and a lower rate of 
premature mortality than people who are 
inactive and sedentary.7–10 Increases in phys-
ical activity over time may be associated with 
improvements in health-related quality of life 
and the stability of MS symptoms.11 12 
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Protocol
strengths and limitations of this study
 ► The iStep-MS trial will investigate the feasibility 
of delivering a behaviour  change intervention to 
increase physical activity and reduce sedentary 
behaviour as part of routine physiotherapy care.
 ► The feasibility of conducting a large randomised 
controlled trial of the clinical effectiveness  and 
cost-effectiveness of the intervention, should the 
intervention prove feasible, will also be determined.
 ► Physical activity and sedentary behaviour will be 
assessed using objective measures. However, all 
other outcome measures are patient reported.
 ► Participants, physiotherapists and researchers 
collecting the data will not be blinded to group 
allocation.
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Although the terms physical activity and exercise 
are often used interchangeably, there is an important 
distinction between them; exercise is a type of phys-
ical activity that is planned, structured and repetitive, 
whereas physical activity includes a broader range of 
activities that result in energy expenditure such as 
occupation-related physical activity, activities of daily 
living and travel-related physical activity.13 Similarly, 
although sedentary behaviour and physical inactivity 
have historically been used synonymously, sedentary 
behaviour is ‘any waking behaviour characterised by 
an energy expenditure ≤1.5 metabolic equivalents, 
while in a sitting, reclining or lying posture’, whereas 
physical inactivity is defined as not meeting physical 
activity recommendations.14
There is substantial evidence that exercise inter-
ventions improve mobility, fatigue, strength, quality 
of life and cardiorespiratory fitness in people with 
MS15–19 but little evidence regarding effective inter-
ventions to increase physical activity in this group. If 
physical activity is not maintained beyond the dura-
tion of an exercise intervention, the benefits of exer-
cise are likely to be short-lived. At present, people 
with MS who want to increase physical activity report 
not receiving support to do so.20
behaviour change interventions
Behaviour change interventions are a potential method 
of increasing physical activity and reducing sedentary 
behaviour in people with MS. Behaviour change inter-
ventions are ‘coordinated sets of activities designed to 
change specified behaviour patterns’.21 These are often 
complex interventions, involving multiple, interacting 
components. Such interventions are commonly used to 
increase physical activity and reduce sedentary behaviour 
in the general population.22–24 Examples of established 
techniques that may be incorporated in interventions 
include goal setting, action planning, providing informa-
tion on the consequences of the behaviour and providing 
feedback on performance of the behaviour.25
A recent meta-analysis indicated that behaviour change 
interventions of approximately 8 to 12 weeks’ duration 
are effective at increasing physical activity in people with 
MS in the immediate period following the intervention.26 
While this suggests that physical activity may be increased 
in the short term, this finding must be interpreted with 
caution. Eight of the 11 studies were judged at being at 
high risk of bias.26 Nine of the 11 studies assessed physical 
activity using self-reported measures, which are likely to 
result in biased estimations of the effect of the interven-
tion given that activity is often overestimated or under-
estimated.27 28 Further, self-reported physical activity may 
be subject to significant reporting bias when participants 
are not blinded to group allocation, as was the case in 
all included studies. While it is rarely possible to blind 
participants to group allocation when examining the 
effectiveness of complex interventions, an objective 
measure of physical activity will prevent recall bias. Of the 
two studies that objectively measured physical activity,29 30 
one reported a significant increase in physical activity 
immediately after a 3-month intervention.29 However, 
this increase was not sustained at 9 months. The second 
study reported no significant increase in objectively 
measured physical activity after a 6-month intervention 
despite improvements in self-reported physical activity.30 
Further, no study included in the review investigated the 
long-term effect of a behaviour change intervention on 
physical activity.
In addition to these methodological limitations, there is 
large variation in the volume (ie, duration and frequency) 
and mode of delivery of interventions across studies. The 
only intervention that resulted in a significant increase in 
objectively measured physical activity following a 3-month 
intervention included 20 exercise consultations, which 
incorporated behaviour change techniques, each lasting 
60 min.29 It may not be feasible or acceptable to deliver or 
receive such a large volume of exercise in clinical prac-
tice, therefore preventing the implementation of the 
intervention into routine care.
Although behaviour change interventions present as a 
potentially effective method of increasing physical activity 
and reducing sedentary behaviour in people with MS, 
the current evidence to support the use of these inter-
ventions for people with MS is limited.26 More research 
is required to identify a feasible, acceptable, clinical-ef-
fectiveness and cost-effective intervention to help people 
with MS increase physical activity and reduce sedentary 
behaviour in the long term.
study objective
The aim of the iStep-MS trial is to determine the safety, 
feasibility and acceptability of a behaviour-change inter-
vention to increase physical activity and reduce sedentary 
behaviour for people with MS. Should the results of this 
study indicate that the intervention is safe, feasible and 
acceptable, it is proposed to investigate the effectiveness 
of the intervention in a larger phase 3 trial.
MEthods
trial design
The iStep-MS trial is a single-centre randomised controlled 
trial with parallel process evaluation comparing a physio-
therapist-led behaviour change intervention to increase 
physical activity and reduce sedentary behaviour in addi-
tion to usual care, with usual care only (figure 1).
MEthods And AnAlysIs
study setting
The study is based in the Berkshire MS Therapy Centre in 
Reading, South East UK.
trial status
At the time of submission of this study protocol, recruit-
ment to the trial is ongoing.
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Figure 1 iStep-MS trial design.
Participants
Participants are eligible to be included in the trial if they 
meet the following inclusion criteria:
1. They have a self-reported diagnosis of MS; this method 
of identifying a diagnosis of MS is consistent with the 
method used in the MS Therapy Centre, which is the 
site for this trial.
2. They are relapse free for the past 3 months; a relapse 
will be defined as ‘the appearance of new symptoms, 
or the return of old symptoms, for a period of 24 hours 
or more, in the absence of a change in core body tem-
perature or infection’.31
3. They are independently ambulatory at a minimum 
within their home with or without a walking aid.
4. They are free of unstable medical conditions, for ex-
ample, unstable angina.
5. They are able to travel to the Berkshire MS Therapy 
Centre for the intervention.
6. They are fluent in English to a standard sufficient for 
completion of the trial assessment and intervention.
7. They have an ability to comprehend and follow all 
instructions relating to participation in the study 
including providing informed consent, completing 
the outcome measures or participating in the 
intervention.
Potential participants will be excluded if they are 
pregnant. Those already participating in a clinical trial 
will also not be permitted to participate to minimise the 
impact of potential confounding variables on the study 
outcome. We have chosen not to limit the eligibility 
criteria to people who are physically inactive or people 
with a specific type of MS as the impact of these factors on 
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study outcomes will be determined following completion 
of this feasibility study. Our analysis of the impact of these 
factors on study outcomes will inform inclusion criteria 
and stratification factors in a definitive trial.
sample size
 Sixty participants will be recruited for this study. This is 
a pilot study and thus a sample size calculation has not 
been performed. There are currently 1200 people on the 
database of the Berkshire MS Therapy Centre. Recruit-
ment rate to the study is estimated to be 10% based on 
previous physical activity studies that include an interven-
tion to change physical activity behaviour.32 33
recruitment
Participants will primarily be recruited from people with 
MS who are registered at the Berkshire MS Therapy 
Centre and meet the eligibility criteria. As it is not possible 
to screen the database at the Therapy Centre to identify 
potentially eligible participants, due to the type of data 
stored on the database, everyone on the database will be 
provided with an information pack by post or email. The 
information pack, sent by an administrator at the centre, 
includes a participant invite letter and a participant 
information sheet. People who receive information by 
post will also receive a questionnaire about their reasons 
for non-participation (described under the "reasons for 
non-participation" section) and a stamped addressed 
envelope. Participants who receive information by email 
will be directed to an online version of the question-
naire. If no response is received within 4 weeks of the first 
contact, the administrator will send a second invitation 
pack containing a new participant invite letter, partici-
pation information sheet, questionnaire and stamped 
addressed envelope (or link to the online version of the 
questionnaire). Information on the study will be shared 
through Berkshire MS Therapy Centre newsletter, blog 
and social media, and posters advertising the study will 
be displayed at the centre. In addition, the study will be 
advertised on the MS Society website. People who express 
an interest in participating in the trial will be contacted 
by a member of the research team who will provide them 
with more information about the study, screen for eligi-
bility and answer questions.
Potential participants identified by the physiotherapy 
team during routine attendance at the MS Therapy 
Centre will also be approached by a member of the 
research team. A member of the physiotherapy team will 
obtain consent from the individual for the member of the 
research team to approach them before they do so. The 
researcher will introduce the study, ensure the person is 
eligible to participate and provide them with an informa-
tion pack.
The study recruitment period will run from May 2017 to 
end January 2018. Over the 9-month recruitment period, 
we expect to recruit 60 participants with MS through 
the Berkshire MS Therapy Centre, which equates to 
approximately 1.5 participants per week. At the time of 
recruitment for this study, there will be no competing 
studies ongoing at the MS Therapy Centre.
reasons for non-participation
A potential concern is that the people who are already 
physically active select to participate in the study. The 
broad inclusion criteria and various recruitment path-
ways aim to counteract this. In addition, the profile of 
participants and non-participants will be compared in 
order to identify potential selection bias. In order to 
identify the reasons why people refuse to participate in 
the study and to identify any differences in baseline char-
acteristics between participants and non-participants, we 
will ask non-participants to complete an online or paper 
questionnaire. Individuals will be asked to provide infor-
mation on sociodemographic factors, health and lifestyle 
factors, and physical activity, and provide reason(s) for 
non-participation. This survey will take approximately 
5 min to complete. Completion of the survey will indicate 
consent. Non-participants will be incentivised to complete 
the questionnaire by being included in a raffle for a £50 
gift voucher on completion of the questionnaire.
randomisation
Following baseline assessments, participants will be 
randomly allocated to the intervention or usual care 
control group in a 1:1 ratio. Allocation will be performed 
by an individual independent to the study according to 
a computer-generated random schedule in permuted 
blocks of 2 or 4. The allocation sequence will be placed 
in sequentially numbered, opaque, sealed envelopes. 
Following each baseline assessment, an envelope will be 
drawn sequentially by a researcher who will inform the 
participant if they are in the intervention group or the 
control group.
blinding
Participants and physiotherapists will not be blind to 
group allocation. Researchers conducting the assess-
ments will also not be blind to group allocation. However, 
the questionnaires will be self-reported and participants 
will receive standardised instructions to mitigate against 
measurement bias. Assessment of objectively measured 
physical activity and sedentary behaviour is unlikely to 
be influenced by the assessor being aware of group allo-
cation. To mitigate against observer bias during data 
processing and analysis, a person independent to the 
study will apply anonymous codes to all data sheets and 
physical activity data files before analysis to ensure that 
the research team and statistician are blinded to group 
allocation when processing and analysing the data.
Intervention
Participants in the intervention group will receive four 
physical activity sessions with a trained physiotherapist 
delivered over 3 months, supported by a handbook and 
pedometer, in addition to usual care. Participants will be 
provided with a handbook prior to session 1.
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The handbook was developed to guide physiothera-
pists and participants through the four physical activity 
sessions. It was developed by cognitive-behavioural 
trainers with experience in training health professionals 
to use brief behaviour change techniques, the research 
team, people with MS and experienced neurolog-
ical physiotherapists. The intervention handbook was 
adapted from the National Health Service (NHS) Health 
Trainer Handbook34 and incorporated aspects from the 
Supportive Adjustment for Multiple Sclerosis (saMS) 
manual.35 The NHS Health Trainer Handbook incorpo-
rates established, effective techniques that help people 
change behaviours that are known to cause ill-health. It 
does not focus on a specific theory of behaviour change 
but incorporates behaviourchange techniques that draw 
from several theories. At present, the NHS Health Trainer 
Handbook is not appropriate for use for the purpose of 
this study as it does not specifically focus on changing 
physical activity and sedentary behaviour and is designed 
for use in the general population. A modified version 
of the NHS Health Trainer Handbook delivered along-
side four supporting consultations has proved effective 
at increasing physical activity in older adults.36 The saMS 
manual was developed to guide a cognitive behavioural 
therapy programme aimed to help people with MS adjust 
to living with MS.35 The specific aspects of the saMS 
manual that were adapted for use in the handbook were 
addressing the particular challenges of MS in relation 
to physical activity, identifying strategies for coping with 
MS-related problems in relation to physical activity and 
reducing ‘symptom focusing’.
The handbook consists of seven sections. The 
content of each section is described in box. An inde-
pendent group of people with MS and physiotherapists 
reviewed and revised each section in consultation with 
the research team. Briefly, the handbook consists of an 
introduction, a section dedicated to each of the four 
sessions and additional resources. The format of the 
sections dedicated to each session is: overview, pre-session 
reading and reflection, content specific to that session 
(eg, barriers and facilitators to physical activity), goal 
setting, and a diary to record and monitor goals. Key 
behaviour change techniques drawn from Michie et al’s 
taxonomy of behaviour change techniques25 were incor-
porated into each session. These included ‘goal setting 
(behaviour)’, ‘action planning’, ‘barrier identification/
problem solving’, ‘set graded tasks’, ‘prompt review of 
behavioural goals’, ‘prompt self-monitoring of behaviour’ 
and ‘provide information on where and when to perform 
behaviour’. Physiotherapists were advised that they did 
not have to cover all aspects of the handbook but may 
focus on specific aspects depending on the needs of 
the individual. However, the participant must set a goal 
relating to step-count, general physical activity and seden-
tary behaviour, in consultation with the physiotherapist, 
at the end of sessions 1, 2 and 3.
Participants in the intervention arm will be provided 
with a Yamax SW-200 digiwalker pedometer at session 
1. The Yamax SW-200 digiwalker has strong concurrent 
validity in adults with MS when compared with accelerom-
etry.37 Participants will be asked to wear the pedometer 
on their trousers or skirt at the right hip for all waking 
hours, except for swimming and bathing, for at least 7 
days between each session. They will record their step-
count and whether or not they achieved their physical 
activity and sedentary behaviour goal for at least 1 week 
between each session in the handbook. Participants will 
be advised that they may record this information for more 
than 1 week.
Session 1 (approximately 45 min duration) will be 
arranged within 10 days of the baseline assessment by 
the physiotherapist. Session 2 (approximately 30 min 
duration) will be scheduled by the physiotherapist for 
2 weeks after session 1. Session 3 (approximately 45 min 
duration) will be scheduled by the physiotherapist for 4 
weeks after session 2. Session 4 (approximately 30 min 
duration) will be scheduled by the physiotherapist for 4 
weeks after session 3.
training
The physiotherapists will be trained by a cognitive-be-
havioural trainer in the use of the handbook as guided 
self-help and will be provided with information regarding 
the behaviour change techniques included in each 
session. This training will comprise of four half days of 
training; two delivered prior to the intervention and two 
delivered during the intervention. Training will be expe-
riential in nature. The physiotherapists will be guided 
through a sequence of learning activities to develop and 
refine their intervention delivery. Key skills such as pacing 
and timing of the sessions will be practised. An additional 
3-hour session with the research team will cover all aspects 
of delivering the trial at the site including maintaining 
the study documentation and teaching participants to use 
the pedometer.
control group
Participants allocated to the control group will receive 
ongoing usual care that could range from intensive phys-
iotherapy to no treatment. Participants’ use of physio-
therapy services will be recorded as part of an assessment 
of their health service use as outlined in the "outcomes" 
section. Participants in both groups will be asked not to 
discuss the intervention with other participants in order 
to avoid participants in the usual care group integrating 
components of the intervention into their routine. The 
impact of allocation to the control group on the partici-
pant will be explored within the process evaluation.
Assessments
Assessments will be completed at baseline, 3 months 
post-randomisation and 9 months post-randomisation. 
Assessments will take place at the Berkshire MS Therapy 
Centre or in the participant’s home with their permission. 
All participants will be requested to complete follow-up 
assessments, including those who withdrew or were 
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box content of the istep-Ms handbook
Section 1: About multiple sclerosis (MS)
 ► An overview of MS and the associated symptoms
 ► The particular challenges of MS
Section 2: About the iStep-MS programme
 ► Overview of the programme
 ► About this handbook
 ► About the physical activity sessions
 ► After the programme
Section 3: Session 1—first steps
 ► Pre-session reading: definitions of physical activity and sedentary behaviour; examples of light, moderate and vigorous intensity activity; physical 
activity guidelines; possible ways to reduce sedentary behaviour and increase physical activity
 ► Pre-session reflection: identify personal examples of light, moderate and vigorous activity that you perform; identify ways to increase your physical 
activity safely; identify the most important values in your life
 ► About you: identify symptoms of MS that affect your ability to carry out physical activity; identify other health conditions that prevent you from doing 
more physical activity; identify other issues that may make increasing physical activity difficult
 ► Benefits of physical activity
 ► Common myths and facts about increasing physical activity with MS
 ► Personal thoughts, worries or emotions concerning increasing physical activity
 ► Summary of current subjectively and objectively measured levels of physical activity and sedentary behaviour
 ► Planning your overall physical activity target
 ► Goal setting: identifying small steps to reach your physical activity target
Section 4: Session 2—overcoming challenges overview
 ► Pre-session reading: the role of thoughts and feelings; coping with MS
 ► Pre-session reflection: identify personal strategies that support coping and improve quality of life; identify personal difficulties and factors than make 
it harder to cope; identify useful tips from pre-session reading regarding how to strengthen personal coping strategies
 ► Reviewing your goals
 ► Barriers and facilitators for physical activity
 ► Overcoming barriers to change—developing positive coping strategies
 ► Goal setting
Section 5: Session 3—keeping up the changes
 ► Pre-session reading: dealing with setbacks; reducing symptom focusing; reducing ‘boom and bust’ activity patterns
 ► Pre-session reflection: identify how you usually deal with setbacks; identify personal setbacks; identify useful tips from pre-session reading on coping 
with setbacks
 ► Reviewing your goals
 ► Strategies for coping with setbacks
 ► Pacing and prioritising
 ► Building ‘if–then’ plans
 ► Goal setting
Section 6: Session 4—building lasting habits
 ► Pre-session reading: reminder of the tips and techniques covered in the handbook
 ► Pre-session reflection: identify difficulties encountered during the programme; identify tips and techniques in the handbook that have proved helpful 
to overcome difficulties
 ► Reviewing your goals
 ► Reviewing progress so far
 ► Reflection on personal experience of programme
 ► Building habits
 ► Planning a new overall physical activity target
Section 7: Additional information and resources
 ► Confidence ruler
 ► Further examples of light, moderate and vigorous intensity activity
 ► Local resources for getting active
withdrawn from the intervention. If participants do not 
respond to the first request to complete a follow-up 
assessment, at least one further contact will be made by 
email or telephone. Assessments will take approximately 
2 hours and participants will be allowed breaks during the 
assessment if required. A pilot assessment was conducted 
to determine the burden of assessment on individuals; 
amendments to the process were made to ensure that the 
burden was minimised.
The following information will be collected at base-
line: (1) socioeconomic information including age, 
gender, ethnicity, employment status and marital status; 
(2) MS-specific information including year of diagnosis, 
type of MS, use of mobility aids, assistive devices such 
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as functional electrical stimulation and ankle and foot 
orthoses, and the MS Impact Scale38; (3) health prob-
lems and lifestyle factors including self-reported chronic 
diseases (eg, hypertension, type 2 diabetes mellitus), 
current medication use, alcohol intake and smoking 
history; and (4) anthropometric measures including 
height, weight, body mass index, waist circumference and 
hip circumference.
The practicality, quality of data, quantity of missing 
data and reasons for missing data associated with the data 
collection tools will be recorded as part of determining 
the feasibility of conducting a phase 3 trial.
outcomes
Objectively measured physical activity and step-count
Physical activity and step-count will be objectively 
measured with the ActiGraph wGT3X-BT accelerom-
eter. Inbuilt sensors detect the magnitude of a person’s 
acceleration in each plane, which is expressed as accel-
erometer counts per unit time when downloaded for 
processing in the ActiLife 6 software. Participants will be 
asked to wear the accelerometer on their right side or 
least effected side in the case of significant asymmetry 
at the hip for 7 days at each assessment point. They will 
be instructed to wear the accelerometer during waking 
hours and remove it for swimming and bathing. They 
will be asked to complete a diary indicating the times 
that they wore the accelerometer. Data will be collected 
in 15 s epochs. Accelerometer counts from the vertical 
axis only will be used for data processing in line with 
the method used to derive a cut-point to classify moder-
ate-to-vigorous physical activity in adults with MS.39 Time 
spent in moderate-to-vigorous physical activity will be 
calculated using the cut-point of 1980 counts per minute 
derived in a group of adults with mild to moderate 
disability.39 Mean counts per minute will be calculated 
to provide an indication of total physical activity.40 The 
ActiGraph accelerometer has previously demonstrated 
excellent reliability for assessing both total activity counts 
and time in moderate-to-vigorous activity among among 
people with MS.41 Average daily step-count will be calcu-
lated from raw activity data collected with the ActiGraph 
wGT3X-BT accelerometer. The ActiGraph accelerometer 
is a valid method of measuring step-count at all walking 
speeds in adults with MS.42
Objectively measured sedentary behaviour
Sedentary behaviour will be measured over 7 days using 
the activPAL3µ activity monitor. The activPAL3µ is a 
small, lightweight device that is worn on the anterior 
aspect of the person’s thigh. It incorporates accelerom-
etry and inclinometry data to provide information on 
the volume of time people spend in sedentary, upright 
and ambulatory activities. Participants will be asked to 
wear the activPAL3µ on their right thigh or least effected 
side. Data will be downloaded and processed using 
activPAL software to provide time in sedentary positions. 
The activPAL was 100% accurate for identifying time in 
sedentary positions versus time in an upright position in 
adults with mobility limitations.43
Self-reported physical activity and sitting
Self-reported time spent in moderate and vigorous 
activity, walking and sitting will be assessed using the 
International Physical Activity Questionnaire (IPAQ) 
short-form. The IPAQ short-form asks participants to 
recall the amount of time they spent in moderate activity, 
vigorous activity, walking and sitting in the past 7 days. 
The IPAQ short-form demonstrated acceptable validity 
and reliability in adults without MS.44 It has also been 
successfully used to investigate the change in seden-
tary behaviour among people with MS following a 
behaviour change intervention.45
Walking capacity
Walking capability will be assessed using the 12-item MS 
Walking Scale (MSWS-12). The MSWS-12 is a self-report 
measure of the impact of MS on a person’s walking capa-
bility over the past 2 weeks.46 Individuals are asked to rate 
the impact of MS on 12 items relating to mobility on a 
scale of 1 to 5 (not at all to extremely) resulting in a total 
score out of 60, which is converted to a percentage. The 
MSWS-12 captures different aspects of walking capability 
including balance, use of support, speed, distance and 
automaticity. The MSWS-12 has demonstrated excellent 
validity and test–retest reliability, and high internal consis-
tency among people with MS across a range of disability 
severities.46 47 A higher score on the MSWS-12 indicates 
poorer walking capability.
Fatigue
Fatigue will be assessed using the Modified Fatigue Impact 
Scale (MFIS). The MFIS assesses the impact of fatigue on 
a person’s activities. Individuals are asked to rate how 
often fatigue affected them in the past 4 weeks on 21 
items. The items can be aggregated into three subscales 
(physical, cognitive and psychosocial). The MFIS demon-
strated high internal consistency, excellent test–retest 
reliability and good construct validity among people with 
MS.48 49 The total MFIS score can range from 0 to 84 with 
a higher score indicating a greater impact of fatigue on a 
person’s activities.
Self-efficacy
Self-efficacy will be assessed using the Multiple Sclerosis 
Self-Efficacy Scale (MSSE). The MSSE assesses an indi-
vidual’s confidence in their ability to perform behaviours 
associated with engaging in activities of daily living and 
managing disease symptoms, reactions and impact 
on activities of daily living. Individuals rate their confi-
dence for each item on a scale of 10 to 100 (very uncer-
tain to very certain).50 The MSSE demonstrates high 
internal consistency, good test–retest reliability and good 
construct validity.50 A higher score on the MSSE indicates 
higher self-efficacy.
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Participation
Participation will be assessed using the Impact on Partic-
ipation and Autonomy Questionnaire (IPA). The IPA 
is a valid and reliable measure of participation and 
autonomy among adults with disability, including people 
with MS.51 52 The IPA contains 32 items, which load on to 
five domains (autonomy indoors, family role, autonomy 
outdoors, social life and relationships, work and educa-
tion). Each item is scored on a scale of 0 to 4 with higher 
scores representing poorer participation and autonomy. 
At least 75% of the domain needs to be completed in 
order to calculate a median score for each domain.
Quality of life
Quality of life will be assessed using the 5 level version 
of the EQ-5D (EQ-5D-5L). The EQ-5D-5L describes 
and values health defined in terms of five dimensions: 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension has five response 
categories ranging from no problems to extreme prob-
lems. Participants are also asked to rate their overall 
health on the day of the interview on a visual analogue 
scale with values ranging from 0 to 100 (EQ-VAS). The 
EQ-5D-5L displayed good discriminatory capacity among 
people with MS.53
Health service use
Health service use will be assessed using a modified 
version of the Client Service Receipt Inventory (CSRI). 
The CSRI collects retrospective information on service 
utilisation, service-related issues and income.54 The CSRI 
has been successfully used to estimate service use among 
adults with MS.55
Economic evaluation
The feasibility of conducting an economic evaluation as 
part of a phase 3 trial of the clinical and cost-effective-
ness of the intervention will be determined by collecting 
data on quality of life and resource use. Specifically, 
the practicality of collecting data on quality of life and 
resource use, the quality of data and quantity of missing 
data will be recorded. Resource use data will include 
(a) training of physiotherapists, (b) sessions (eg, dura-
tion and frequency) provided by physiotherapists and 
(c) provision of handbooks and pedometers. Out-of-
pocket expenses related to participation in physical 
activity (eg, equipment costs) and travel to and from 
the intervention sessions will also be collected as partic-
ipation in physical activity interventions could increase 
the private costs of physical activity and impact on 
cost-effectiveness.56 57 Data will be collected through key 
informant interviews (participants and physiotherapists), 
review of trial records, adapted client service receipt 
inventory and participants’ questionnaires at baseline, 3 
months and 9 months.
In a definitive trial, the cost-effectiveness analysis (from 
baseline to 9 months post-randomisation) of the inter-
vention against usual care will take NHS, personal social 
services and participants’ perspective.58 Unit costs will be 
taken from the NHS reference costs (eg, DH 2015/16), 
standard unit costs (eg, PSSRU 2016) and published liter-
ature. The main outcome of the economic analysis will be 
an incremental cost per quality-adjusted life-year, based 
on EQ-5D-5L.
Process evaluation
A parallel process evaluation will be conducted alongside 
the randomised controlled trial in order to determine the 
feasibility and acceptability of the intervention.
The feasibility of delivering the intervention will be 
assessed through multiple mechanisms following the 
guidelines for fidelity in complex rehabilitation inter-
ventions.59 Specifically, the feasibility of training physio-
therapists to conduct the trial and perceived adequacy 
of training will be assessed by recording attendance at 
the training and gathering subjective data at the end 
of the study through semistructured interviews with all 
participating physiotherapists. Informed consent will be 
obtained from physiotherapists prior to conducting the 
interview.
The feasibility and acceptability of the intervention 
for people with MS will be assessed by evaluating fidelity 
to programme receipt through the assessment of atten-
dance at sessions, evaluating fidelity to programme task 
through the assessment of rates of completion of the 
handbook and exploring the experience of participation 
through semistructured interviews with 15 participants 
from the intervention group and 10 participants from the 
control group at the end of the study period. Sampling 
of participants to participate in interviews will involve key 
criteria such as gender, age, type of MS and level of base-
line walking ability to ascertain a range of views.
Fidelity
Fidelity to the programme will be assessed through 
fidelity to intervention content and delivery skills. The 
content parallels the main skills identified in the interven-
tion itself. Skills relate to delivery skills of the therapists 
including empathic listening, partnership working and 
motivational interviewing, all part of the training deliv-
ered to the therapists. A fidelity tool has been developed 
by an expert panel consisting of experienced cognitive-be-
havioural trainers involved in intervention development. 
Prior to its use in the trial, the tool will be piloted by 
three raters (two members of the research team and a 
cognitive-behavioural trainer) independently rating four 
different recorded sessions. All therapists delivering the 
intervention will have each of the four sessions assessed 
with the specific sessions selected at random, ensuring a 
minimum of 10% of each therapists’ sessions are assessed. 
Assessment will occur through audio-recordings of the 
sessions and no feedback will be given to the therapists .
Fidelity to intervention content will be achieved if 70% 
of appropriate content is covered either completely or 
partially within a session. This acknowledges that for some 
individuals, certain content may not be appropriate and 
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can therefore be removed from the assessment. Fidelity 
to delivery skills will be achieved if the therapist is scored 
at an adequate level or above in each of the designated 
skill categories.
Interviews
Interviews will be conducted in person or over the phone. 
In-person interviews will be held in a private room at the 
Berkshire MS Therapy Centre or in the participant’s 
home. The interviews will be conducted by an experi-
enced qualitative researcher following topic guides devel-
oped from relevant literature and the specific aims of the 
process evaluation.
Safety
The safety of the intervention will be determined by 
assessing pain and fatigue at baseline, 3 months and 9 
months, and recording the incidence of adverse events 
(AEs), including falls and relapses from the time of base-
line measures until the end of the trial for each partic-
ipant. Pain will be assessed using the section relating 
to pain on the EQ-5D-5L. Fatigue will be assessed using 
the MFIS. At each assessment point, participants will 
be asked if they experienced a fall, a relapse or any AE 
since the last contact. Although this method of assessing 
falls relies on the recall ability of the participant, it accu-
rately detects injurious falls in community-dwelling older 
adults.60 Participants will also be advised to contact the 
research team if they experience an AE during the trial. 
An adverse event is considered serious if it results in death, 
is life-threatening, requires hospitalisation or prolonga-
tion of existing hospitalisation and results in persistent 
or significant disability or incapacity. All serious adverse 
events (SAEs) will be reported to the trial Sponsor and 
Research Ethics Committee within 48 hours of a member 
of the research team or the physiotherapy team at the MS 
Therapy Centre first becoming aware of the SAE. The 
Trial Steering Committee (TSC) will be notified of all 
AEs. Participants who experience a SAE will be withdrawn 
from the study.
A summary of all data collected and when these are 
collected is provided in table 1.
data management
Personal data collected during the trial will be handled 
and stored in accordance with the 1998 Data Protection 
Act. All data will be stored securely to maintain confi-
dentiality. To preserve the participant’s anonymity, only 
their allocated trial number and initials will be recorded 
on any trial documentation except for the consent form 
and contact details. Documents with identifiable informa-
tion will be stored separately to other study documents. 
Pseudonyms will be used when reporting findings from 
qualitative research. The use of the data from the study 
will be controlled by the Chief Investigator. All data and 
documentation related to the trial will be stored in accor-
dance with applicable regulatory requirements and access 
to data will be restricted to authorised trial personnel. 
Pseudonymised quantitative data will be made available 
in a public repository once the data have obtained valida-
tion through publication.
service user involvement
People with MS have been involved in the development 
of the protocol and will be included in all stages of the 
study. The need for the study was highlighted through 
interviews with people with MS. A reference group of two 
people with MS and four experienced neurological phys-
iotherapists was developed to advise the research team. 
The reference group contributed to the development of 
the intervention and assisted with piloting the interven-
tion and creating materials for training physiotherapists. 
The reference group also reviewed the documentation 
developed for the trial, including participant information 
sheets, participant invite letters and questionnaires. A 
member of the reference group also assisted with piloting 
the assessment. The reference group will continue to 
advise the research team on recruitment, retention and 




In order to determine the feasibility and acceptability of 
the intervention among both people with MS and phys-
iotherapists, interviews from both groups (physiothera-
pists and people with MS) will be analysed independently 
through framework analysis.61 This method of analysis 
provides a clear audit trail of the analytical process, 
which enhances transparency.62 The technique involves 
five iterative stages of analysis: familiarisation, identifying 
thematic framework, labelling, charting, and mapping 
and interpretation,62 following which significant themes 
can be presented. Further steps to enhance rigour in this 
process including peer debriefing will be put in place 
and reported. NVIVO will be used for interview data 
management.
Quantitative data
To determine fidelity to the intervention, descriptive 
statistics will be used to describe the number of sessions 
received by participants, the time between each session 
and the duration of each session. The percentage of 
participants who receive at least 70% of appropriate 
content, either completely or partially, within a session 
will be reported.
To determine acceptability of the intervention, descrip-
tive statistics will be used to report attendance at physical 
activity consultations, completion rate of the handbook 
and completion of the physical activity diary.
To determine safety of the intervention, descriptive statis-
tics will be used to report fatigue and pain at baseline, 3 
months and 9 months, respectively. Linear mixed models 
will be used to assess differences in changes in pain and 
fatigue during follow-up between groups. Descriptive statis-
tics will be used to report the number of adverse events, 
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Table 1 Data collected throughout the participant’s involvement in the trial
Baseline
During 
intervention 12 weeks 9 months Other
Baseline information
  Socioeconomic information ✓
  MS-specific information ✓
  MS Impact Scale ✓
  Self-reported history of chronic disease and medication use ✓
  Self-reported history of lifestyle factors ✓
  Anthropometric measures ✓
Outcomes (measures)
  Daily moderate-to-vigorous physical activity (ActiGraph GT3x-BT) ✓ ✓ ✓
  Total daily physical activity (ActiGraph GT3x-BT) ✓ ✓ ✓
  Daily step count (ActiGraph GT3x-BT) ✓ ✓ ✓
  Time in sedentary, upright and ambulatory activities (activPAL3µ) ✓ ✓ ✓
  Self-reported daily time in moderate-to-vigorous activity and walking 
(IPAQ short-form)
✓ ✓ ✓
  Self-reported daily time in sitting (IPAQ short-form) ✓ ✓ ✓
  Walking capability (12-item MS Walking Scale) ✓ ✓ ✓
  Fatigue (Modified Fatigue Impact Scale) ✓ ✓ ✓
  Self-efficacy (Multiple Sclerosis Self-Efficacy Scale) ✓ ✓ ✓
  Participation (Impact on Participation and Autonomy Questionnaire) ✓ ✓ ✓
  Quality of life (EQ-5D-5L) ✓ ✓ ✓
  Health service use (adapted Client Service Receipt Inventory) ✓ ✓ ✓
  Resource use ✓
  Out-of-pocket expenses related to participation in physical activity ✓ ✓ ✓




  Physiotherapist attendance at training* ✓
  Attendance at physical activity sessions ✓
  Rate of completion of handbook† ✓
  Fidelity to the intervention† ✓
  Incidence of adverse events (including falls and relapses)‡ ✓ ✓ ✓
  Semistructured interviews with participants ✓
  Semistructured interviews with physiotherapists§ ✓
*Data collected prior to start of intervention delivery.
†Assessed among participants in intervention group only.
‡Data collected throughout a participant’s involvement in the trial (9 months) but participants only specifically questioned at these time points.
§Data collected after physiotherapists have completed delivery of intervention.
IPAQ, International Physical Activity Questionnaire; MS, multiple sclerosis.
including falls and relapses, in each group for the duration 
of the trial. A negative binomial model, which accounts for 
overdispersion in the outcome, will be used to investigate if 
the number of adverse events differ between groups. Partic-
ipants with data recorded at at least one follow-up assess-
ment will be included in the analysis. The type and severity 
of the adverse event will be described.
As this is a feasibility study, the efficacy of the interven-
tion is not of primary interest. However, exploratory anal-
ysis will be conducted to examine how outcomes differ 
between the intervention and control group over time. 
A detailed statistical analysis plan will be made prior to 
the analysis. It is anticipated that linear mixed models, to 
account for within-participant correlation, will be used to 
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determine the difference in objectively measured moder-
ate-to-vigorous activity, step-count, sedentary behaviour, 
walking capability, fatigue, self-efficacy and participation 
between groups at 3 months and 9 months. The baseline 
score for the relevant outcome will be included in the 
model as a covariate in order to improve precision of the 
effect estimate.
The primary analysis will be an intention-to-treat anal-
ysis. A secondary per-protocol analysis will be conducted 
using participants who attended at least 75% of the 
sessions and completed follow-up to 9 months. The 
amount and mechanism of missing data will be explored. 
If data are only missing in the outcome and the miss-
ingness mechanism is assumed to be MAR (missing at 
random), linear mixed models provide an unbiased and 
efficient estimate of the treatment effect.63 Sensitivity 
analyses will be conducted to determine if the assump-
tion of MAR is reasonable.64
All analyses will be conducted using Stata (StataCorp).
The following criteria are proposed to determine if the 
intervention warrants further investigation in a larger phase 
3 trial: there is no evidence of a greater number of adverse 
events or a greater negative change in pain and fatigue in 
the intervention group in comparison to the control group; 
there is no indication of a dominant negative theme from 
interviews with participants and physiotherapists; and the 
attrition rate is less than 20%. In addition, if these criteria 
are met, data collected during interviews will be used to 
adapt the intervention in order to improve its acceptability 
for use in a definitive trial.
timeline
The trial is funded for a period of 24 months and 
commenced in January 2017. This includes time to 
develop the intervention. Recruitment commenced in 
May 2017 and is projected to be completed by January 
2018. The final follow-up assessment is projected to be 
completed by September 2018 with data analysis and 
report writing being conducted from month 21 onwards.
Ethics
The study is sponsored by Brunel University London. 
Any protocol modifications will be communicated to the 
Brunel University London Ethics Committee and consent 
will be reobtained from participants if the Research Ethics 
Committee deems it necessary. The trial will be conducted 
in full conformance with the principles of the Declaration 
of Helsinki and to Medical Research Council Good Clin-
ical Practice (GCP) guidelines. All researchers working on 
the trial will receive training in GCP guidelines. It will also 
comply with all applicable Brunel University Research integ-
rity guidance.
Consent will be obtained from the manager of the 
Berkshire MS Therapy Centre to conduct the research at 
the centre. All participants will freely give their informed 
consent to participate in the trial. Additional informed 
consent will be obtained from individuals sampled to 
participate in semistructured interviews.
Monitoring
Due to the low risk nature of the intervention, we do not 
anticipate any potential harms and therefore there will be 
no Data Monitoring Committee, interim analyses or stop-
ping rules.
Administrative structures
The trial will be run by the trial management group, 
which consists of the Chief Investigator, co-Chief Inves-
tigator, co-Investigators and two Research Fellows. The 
conduct of the trial will be supervised by a TSC.
dissemination
A detailed dissemination plan will be developed in the 
early phases of the trial in collaboration with the TSC. The 
results will be disseminated to all participants and partic-
ipating physiotherapists through study summary docu-
ments and presentations at the MS Therapy Centre. The 
results of the trial will also be published in a peer-reviewed 
journal and presented at National and International MS 
conferences. The trial will be reported in line with the 
Consolidated Standards of Reporting Trials (CONSORT) 
statement. Authorship will be based on the International 
Committee of Medical Journal Editors criteria.
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